OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Some of OGM's novel findings, however, are difficult for other methods to validate, because of their resolution limitations. In this paper, researchers used OGM to detect variants in the BMA samples that were missed by traditional methods, and then applied targeted Cas9-directed Nanopore sequencing to validate the variants detected with OGM and define the breakpoints at the base pair level. The study results highlight OGM's ability to provide researchers with a more comprehensive understanding of leukemia subtypes and the potential of targeted Cas9-directed Nanopore sequencing to validate new findings efficiently and at high resolution, compared to other genome analysis methods, including short read or other long read sequencing methods.
'We were pleased to see researchers conclude that the findings detected by OGM in leukemia samples were robust and superior to classical cytogenetic methods. When these findings are validated with Cas9-directed Nanopore sequencing, we believe the result is a powerful whole genome analysis tool that has the potential to identify pathogenically relevant SVs and further our understanding of molecular subtypes in blood cancer,' commented
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its
Forward-Looking Statements of Bionano
This press release contains forward-looking statements contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'ability,' 'believe,' 'potential, 'shown' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability and utility of OGM to regularly detect SVs missed by other cytogenetic methods; the ability and utility of Cas-9 directed LRS to validate SVs detected using OGM; the ability and utility of OGM to detect SVs relevant to blood cancers and other statements that are not historical facts.
Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and future bank failures, the ongoing conflicts between
Contact:
Tel: +1 (858) 888-7610
Email: eholmlin@bionano.com
Tel: +1 (858) 888-7625
Email: IR@bionano.com
(C) 2024 Electronic News Publishing, source